It has been reported that the inhibition of MYC in AML cell lines drastically induces cell differentiation [46], and studies in mice have demonstrated that even transient inactivation of MYC yields tumor regression [47], supporting the hypothesis that targeting MYC regulation could be a highly pursued goal to treat cancer patients. This evidence concerns the gene MYC and acute myeloid leukemia.